Literature DB >> 9736744

Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy.

T Kafri1, D Morgan, T Krahl, N Sarvetnick, L Sherman, I Verma.   

Abstract

Replication-defective adenoviral (RDAd) vectors can be generated at high titers and infect both dividing and nondividing cells. Long term expression in the transduced tissue, however, has been a problem because of the cellular immune responses against the infected cells. We demonstrate that mice injected with RDAd vectors containing mouse leptin gene reduce food intake and lose weight for only 7 to 10 days. Splenocytes obtained from infected mice are able to lyse target cells infected with RDAd vectors. Surprisingly, target cells infected with psoralen-treated, UV-crosslinked, biologically inactive RDAd also were lysed efficiently by the effector cells. Furthermore, splenocytes obtained from mice injected with inactive RDAd vectors efficiently lysed target cells infected with RDAd vectors. Whether RDAd vectors were injected i.m. or i.v. or through an i.p. route, the extent of lysis was similar. We propose that cells infected with RDAd vectors present antigens for recognition by class 1 major histocompatibility complex-restricted cytotoxic T lymphocytes by a mechanism that does not require viral replication or de novo protein synthesis. These results should prompt reevaluation of the use of RDAd vectors for gene therapy when long-term expression is required.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736744      PMCID: PMC21650          DOI: 10.1073/pnas.95.19.11377

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  CD8 is needed for development of cytotoxic T cells but not helper T cells.

Authors:  W P Fung-Leung; M W Schilham; A Rahemtulla; T M Kündig; M Vollenweider; J Potter; W van Ewijk; T W Mak
Journal:  Cell       Date:  1991-05-03       Impact factor: 41.582

2.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Authors:  Y Yang; F A Nunes; K Berencsi; E E Furth; E Gönczöl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

Review 3.  Gene therapy: adenovirus vectors.

Authors:  K F Kozarsky; J M Wilson
Journal:  Curr Opin Genet Dev       Date:  1993-06       Impact factor: 5.578

4.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.

Authors:  J F Engelhardt; X Ye; B Doranz; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

5.  Genetic analysis of adenoviruses.

Authors:  T Shenk; J Williams
Journal:  Curr Top Microbiol Immunol       Date:  1984       Impact factor: 4.291

6.  Persistence in muscle of an adenoviral vector that lacks all viral genes.

Authors:  H H Chen; L M Mack; R Kelly; M Ontell; S Kochanek; P R Clemens
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

7.  Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression.

Authors:  S R Riddell; M Rabin; A P Geballe; W J Britt; P D Greenberg
Journal:  J Immunol       Date:  1991-04-15       Impact factor: 5.422

8.  Stepwise dismantling of adenovirus 2 during entry into cells.

Authors:  U F Greber; M Willetts; P Webster; A Helenius
Journal:  Cell       Date:  1993-11-05       Impact factor: 41.582

Review 9.  Adenovirus-mediated in vivo gene transfer.

Authors:  S L Brody; R G Crystal
Journal:  Ann N Y Acad Sci       Date:  1994-05-31       Impact factor: 5.691

10.  In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.

Authors:  M A Kay; C N Landen; S R Rothenberg; L A Taylor; F Leland; S Wiehle; B Fang; D Bellinger; M Finegold; A R Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

View more
  60 in total

1.  Herpes simplex virus triggers and then disarms a host antiviral response.

Authors:  K L Mossman; P F Macgregor; J J Rozmus; A B Goryachev; A M Edwards; J R Smiley
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Episomal segregation of the adenovirus enhancer sequence by conditional genome rearrangement abrogates late viral gene expression.

Authors:  X Wang; W Zeng; M Murakawa; M W Freeman; B Seed
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus.

Authors:  D Maione; C Della Rocca; P Giannetti; R D'Arrigo; L Liberatoscioli; L L Franlin; V Sandig; G Ciliberto; N La Monica; R Savino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

4.  Differential T-cell activation by B7-1 expression.

Authors:  Wei Li; Anthony Rosenzweig; Brigitte T Huber
Journal:  Immunology       Date:  2003-07       Impact factor: 7.397

5.  Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression.

Authors:  Jackie L Stilwell; Douglas M McCarty; Atsuko Negishi; Richard Superfine; R Jude Samulski
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 6.  Gene therapy: light is finally in the tunnel.

Authors:  Huibi Cao; Robert S Molday; Jim Hu
Journal:  Protein Cell       Date:  2012-01-10       Impact factor: 14.870

Review 7.  Applying horizontal gene transfer phenomena to enhance non-viral gene therapy.

Authors:  Jacob J Elmer; Matthew D Christensen; Kaushal Rege
Journal:  J Control Release       Date:  2013-08-30       Impact factor: 9.776

Review 8.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

Review 9.  Gene therapy and wound healing.

Authors:  Sabine A Eming; Thomas Krieg; Jeffrey M Davidson
Journal:  Clin Dermatol       Date:  2007 Jan-Feb       Impact factor: 3.541

10.  Human adenovirus type 37 and the BALB/c mouse: progress toward a restricted adenovirus keratitis model (an American Ophthalmological Society thesis).

Authors:  James Chodosh
Journal:  Trans Am Ophthalmol Soc       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.